Chris Aiken, MD.
Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.
Secuado, the first transdermal patch for schizophrenia, is newly approved version of asenapine (aka Saphris). It promises to reduce side effects and enhance adherence. However, it adds a new side effect of its own, and transdermal delivery isn’t clearly better than sublingual, which is how the older Saphris is absorbed.